Vasopressin Receptor

特异性亚型抑制剂

• Vasopressin receptor 1
• Vasopressin receptor 2 Selective

Vasopressin Receptor产品

目录号	产品描述	文献引用	实验数据
S2116	Conivaptan HCl Conivaptan HCl 是一种非肽类抗利尿激素抑制剂（加压素受体拮抗剂）。	Antimicrob Agents Chemother, 2017, AAC.01674-17 Sci Rep, 2017, 7(1):12881	Select hit drugs from each class identified from the Selleck screen were assayed at 0.25X, 0.5X, and 1X MIC for their ability to prevent biofilm formation in vitro. Data were normalized to DMSO control. * p<0.05 (Student’s t-Test; two-tailed).
S2593	Tolvaptan Tolvaptan (OPC-41061)是一种选择性，竞争性的精氨酸加压素受体2拮抗剂，抑制AVP-诱导的血小板聚集，IC50为1.28µM。	Acta Physiol (Oxf), 2021, 10.1111/apha.13661 J Mol Cell Biol, 2020, 12(8):644-653 Am J Physiol Renal Physiol, 2015, 309(5):F474-83	Immunoblots of inner medullas from control and tolvaptan-treated rats. Each lane was loaded with a sample from a different rat. Tolvaptan (2.5 mg/day) or vehicle was infused for 4 days. Loading: aquaporin-2 (AQP2), 15 μg; AQP3, 20 μg; AQP4, 25 μg; and urea transporter UT-A1, 25 μg. Values are normalized band densities covering all bands (means ± SE). *Statistical significance (P < 0.05, t-test).
S2815	Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) 是一种口服、非肽、选择性 V2 受体（V2 receptor） 加压素拮抗剂，对人 V2 受体和大鼠 V2 受体的 IC50 分别为 1.2 nM 和 2.3 nM。
S2920	Mozavaptan Mozavaptan (OPC-31260)是一种新型，竞争性的vasopressin受体拮抗剂，作用于V1和V2受体，IC50分别为1.2 μM和14 nM。	Life Sci, 2019, 10.1016/j.lfs.2019.05.049 Am J Med Sci, 2019, 357(3):247-254
P1084	Desmopressin Acetate Desmopressin是一种合成的八肽，是人源激素精氨酸加压素的类似物，具有抗利尿和促凝作用。

目录号	产品描述	文献引用	实验数据
S2116	Conivaptan HCl Conivaptan HCl 是一种非肽类抗利尿激素抑制剂（加压素受体拮抗剂）。	Antimicrob Agents Chemother, 2017, AAC.01674-17 Sci Rep, 2017, 7(1):12881	Select hit drugs from each class identified from the Selleck screen were assayed at 0.25X, 0.5X, and 1X MIC for their ability to prevent biofilm formation in vitro. Data were normalized to DMSO control. * p<0.05 (Student’s t-Test; two-tailed).
S2593	Tolvaptan Tolvaptan (OPC-41061)是一种选择性，竞争性的精氨酸加压素受体2拮抗剂，抑制AVP-诱导的血小板聚集，IC50为1.28µM。	Acta Physiol (Oxf), 2021, 10.1111/apha.13661 J Mol Cell Biol, 2020, 12(8):644-653 Am J Physiol Renal Physiol, 2015, 309(5):F474-83	Immunoblots of inner medullas from control and tolvaptan-treated rats. Each lane was loaded with a sample from a different rat. Tolvaptan (2.5 mg/day) or vehicle was infused for 4 days. Loading: aquaporin-2 (AQP2), 15 μg; AQP3, 20 μg; AQP4, 25 μg; and urea transporter UT-A1, 25 μg. Values are normalized band densities covering all bands (means ± SE). *Statistical significance (P < 0.05, t-test).
S2815	Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) 是一种口服、非肽、选择性 V2 受体（V2 receptor） 加压素拮抗剂，对人 V2 受体和大鼠 V2 受体的 IC50 分别为 1.2 nM 和 2.3 nM。
S2920	Mozavaptan Mozavaptan (OPC-31260)是一种新型，竞争性的vasopressin受体拮抗剂，作用于V1和V2受体，IC50分别为1.2 μM和14 nM。	Life Sci, 2019, 10.1016/j.lfs.2019.05.049 Am J Med Sci, 2019, 357(3):247-254

目录号	产品描述	文献引用	实验数据
P1084	Desmopressin Acetate Desmopressin是一种合成的八肽，是人源激素精氨酸加压素的类似物，具有抗利尿和促凝作用。